Menu Close

Growth is the catalyzing ingredient in our successful journey


CORONA principles & strong Internal SOP in compliance with global policies helped us for better Integration

CORONA acquired the brands Vitneurin, Stelbid, Dilo DX, and Dilo BM from GSK and consolidated position in nutraceuticals, respiratory, and gastroenterology segments.

CORONA also acquired the Obimet and Thyrocab range of brands from Abbott India and strengthened therapy presence in Diabetes & Thyroid management.

Strategic alliances


In India and Europe, La Chandra Pharma Lab has emerged as the go-to name for APIs. LCPL is the solution provider for complex, niche, and challenging APIs.

La-Chandra Pharma owns EUGMP approval for various API’s. In the Indian market, La-Chandra Pharma enjoys a leadership position in hormonal API.

LCPL build its human capital with technocrats, Doctorates, Scientists, Engineers & Microbiology experts. LCPL runs robust quality enhancement programmes and strongly believes in training and development of the team.

LCPL has numerous research and development collaborations with MIT-Boston in the United States, a CRO in the Netherlands, and others.

LCPL is poised for rapid increase in International business. They are in advanced discussions with global manufacturers for niche API/intermediate supply. 

Co-Marketing’ partnership between ALBERT DAVID & CORONA

The human placental extract product is an old and well-established product of Albert David Ltd. It is prescribed by Gynaecologists for PID (pelvic inflammatory disease). It has various other applications and usages and has great trust from senior and experienced clinicians.

Gel is being prescribed by surgeons, physicians, and other doctors for wound healing and other applications.CORONA has launched PLAKONTA, a new brand of “Human Placental Extract” with technical support and supply of ADL. PLAKONTA Injection and Gel.

The synergistic approach to pricing and promotion will lead to market expansion and we are sure that Co-Marketing’ partnership with ADL & CORONA will make a wonder product widely available & used by fraternity which will help ailing community.

Together to reach newer heights

In licensing

Good Health For All – Our moto behind access for affordable health requires us to work with partners across the healthcare value chain. We have strong network of healthcare professionals, hospitals; deep penetrated distribution & Pharmacy coverage. We work with all of them always keeping the end consumer – the patient at the center of all we do.

We focus on our partners with a high-value strategic mind-set and who place a value proposition on quality, compliance and relationships.

Ensuring continuous product supply, best marketing practices & strong distribution network are vital to provide medicines to patients worldwide.

To achieve this, we work with business partners in various ways across the value chain. We emphasize fair, transparent and ethical practices and seek partners who share the same commitment towards compliance with laws, regulations, published standards and environmental practices.

Out licensing

CORONA is aggressively seeking valuable partner across the globe for its formulations, differentiated and indigenously developed products. Be it generic or value added products, CORONA products are developed at DSIR approved R&D setup with strong backup of science & proven product stability. Global out-licensing & strategic collaboration, can give our partners access to a varied range of the most sought after innovative products and ready to go medico – marketing support.

Kindly reach out and explore the opportunities in partnering with CORONA, we’d love to hear about your products and services.

Be Our Partner